FORM	4
------	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB	APPROVAL
OIVID	AFFROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person*	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
<u>Slater Eve Elizabeth</u>	MA [VRTX]	X	Director	10% Owner						
(Last) (First) (Middle)			Officer (give title below)	Other (specify below)						
C/O VERTEX PHARMACEUTICALS INCORPORATED	3. Date of Earliest Transaction (Month/Day/Year) 05/29/2007									
130 WAVERLY STREET	4. If Amendment, Date of Original Filed (Month/Day/Year)	vidual or Joint/Group Filin	Filing (Check Applicable							
(Street)		X	Form filed by One Rep	porting Person						
CAMBRIDGE MA 02139			Form filed by More that Person	an One Reporting						
(City) (State) (Zip)										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities A Disposed Of (5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	05/29/2007		М		10,000	Α	\$13.32	11,105 ⁽¹⁾	D	
Common Stock	05/29/2007		S		10,000	D	\$30.42	1,105 ⁽¹⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$13.32	05/29/2007		м			10,000	06/01/2005 ⁽²⁾	05/31/2015	Common Stock	10,000	\$ 0	0	D	

Explanation of Responses:

1. Dr. Slater disclaims beneficial ownership of 1,105 shares, which are held jointly with her adult son.

2. Right to buy under 1996 Stock and Option Plan. Fully vested.

Remarks:

Kenneth S. Boger, Attorney-In-05/30/2007

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.